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Abstract
The role of neuroinflammation in the mechanisms of epilepsy development is important because inflammatory
mediators provide tractable targets for intervention. Inflammation is intrinsically involved in the generation of
childhood febrile seizures (FSs), and prolonged FS [febrile status epilepticus (FSE)] precedes a large proportion
of adult cases of temporal lobe epilepsy (TLE). As TLE is often refractory to therapy and is associated with serious
cognitive and emotional problems, we investigated whether its development can be prevented using anti-
inflammatory strategies. Using an immature rat model of FSE [experimental FSE (eFSE)], we administered
dexamethasone (DEX), a broad anti-inflammatory agent, over 3 d following eFSE. We assessed eFSE-provoked
hippocampal network hyperexcitability by quantifying the presence, frequency, and duration of hippocampal
spike series, as these precede and herald the development of TLE-like epilepsy. We tested whether eFSE
provoked hippocampal microgliosis, astrocytosis, and proinflammatory cytokine production in male and female
rats and investigated blood–brain barrier (BBB) breaches as a potential contributor. We then evaluated whether
DEX attenuated these eFSE sequelae. Spike series were not observed in control rats given vehicle or DEX, but
occurred in 41.6% of eFSE-vehicle rats, associated with BBB leakage and elevated hippocampal cytokines. eFSE
did not induce astrocytosis or microgliosis but provoked BBB disruption in 60% of animals. DEX significantly
reduced spike series prevalence (to 7.6%) and frequency, and abrogated eFSE-induced cytokine production and
BBB leakage (to 20%). These findings suggest that a short, postinsult intervention with a clinically available
anti-inflammatory agent potently attenuates epilepsy-predicting hippocampal hyperexcitability, potentially by
minimizing BBB disruption and related neuroinflammation.
Significance Statement
Epilepsy is the third most common brain disorder. Temporal lobe epilepsy (TLE) involves limbic circuits and
commonly provokes serious cognitive and emotional problems. Because TLE is often refractory to therapy,
its prevention would be a powerful and clinically important strategy. A large proportion of TLE follows long
childhood febrile seizures [febrile status epilepticus (FSE)], which intrinsically involves neuroinflammation.
Here we used dexamethasone (DEX), a broad anti-inflammatory agent, commencing after experimental FSE
(eFSE). Transient DEX administration significantly reduced the prevalence and frequency of spike-series, a
surrogate marker of network hyperexcitability. The mechanism likely involved the repression by DEX of
eFSE-induced cytokine production and blood–brain barrier disruption. Our data demonstrate the efficacy
of mechanism-driven post-insult intervention in mitigating epileptogenesis, with significant translational
potential
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Introduction
Temporal lobe epilepsy (TLE) is the most common hu-
man focal epilepsy. TLE is characterized by hippocampal
seizures and is associated with cognitive and emotional
problems. Prolonged childhood febrile seizures [febrile
status epilepticus (FSE)] precede a majority of adult TLE
(Cendes et al., 1993; French et al., 1993) and may con-
tribute to TLE development (Annegers et al., 1987; Cen-
des et al., 1993; Dubé et al., 2007; Lewis et al., 2014;
Yokoi et al., 2019). To elucidate potential mechanisms by
which FSE promotes epilepsy, immature rat models of
experimental FSE (eFSE) have been created (Baram et al.,
1997; Heida et al., 2004; Heida and Pittman, 2005; Dubé
et al., 2010b; Reid et al., 2013). The FSE model developed
by the authors promotes epilepsy in 40% of rats, similar
to findings in humans (Dubé et al., 2006, 2010b; Choy
et al., 2014).
Inflammation has been implicated in both the develop-
ment of epilepsy (epileptogenesis) and its progression
and comorbidities (Vezzani et al., 2011b). Inflammatory
markers have been identified in hippocampi removed
from individuals with TLE and in animal models (Aronica
and Gorter, 2007; Dubé et al., 2007; Balosso et al., 2013).
Inflammation is intrinsically involved in FSE because of its
role in fever generation (Luheshi et al., 1997; Cartmell
et al., 1999; Reid et al., 2009; Eskilsson et al., 2014).
Previous work has demonstrated that the cytokine in-
terleukin (IL)-1 is a crucial component of eFSE genera-
tion (Dubé et al., 2005; Heida and Pittman, 2005). In
addition, higher hippocampal IL-1 levels were found in
animals that become epileptic after eFSE (Dubé et al.,
2010b). Notably, rats destined to become epileptic had
increased hippocampal levels of several proinflammatory
molecules within hours following eFSE (Patterson et al.,
2015). These included cyclooxygenase 2 (COX2), GFAP
(an astrocyte activation marker), TNF-, and IL-1 receptor
1 (IL-1R1; Dubé et al., 2005, 2007, 2010b; Patterson et al.,
2015). Thus, inflammation is an attractive target for anti-
epileptogenic therapies aiming to abort the process initi-
ated by FSE and prevent spontaneous seizures (Vezzani
et al., 2011b; Dedeurwaerdere et al., 2012; Jiang et al.,
2013; Patterson et al., 2014).
Neuroinflammation often provokes blood–brain barrier
(BBB) breaches because inflammatory cytokines, prosta-
glandins and other mediators disrupt endothelial tight
junctions that contribute to the BBB (Abbott, 2000). In-
creased BBB permeability allows the entry of molecules
and cells from peripheral tissues. These further enhance
inflammation and the risk of future seizures (Seiffert et al.,
2004; Friedman, 2011; Janigro, 2012), likely because the
peripheral cells and molecules promote neuronal injury
and further inflammation, creating a vicious injurious cycle
(Gorter et al., 2019). Importantly, several insults that pro-
mote epileptogenesis lead to early BBB breaches (Tom-
kins et al., 2008; Bar-Klein et al., 2017). Yet, whether eFSE
causes breakdown of the BBB and whether anti-
inflammatory agents mitigate these potential BBB disrup-
tions has not been studied.
Several interrelated inflammatory cascades are trig-
gered by FSE (Vezzani et al., 1999; Reid et al., 2009;
Patterson et al., 2015; Brennan et al., 2016). The interac-
tions among these pathways are complex, including feed-
back and compensation (Vezzani et al., 2011b). Therefore,
it is not surprising that targeting specific pathways has
had little efficacy in preventing eFSE-induced hyperexcit-
ability (Brennan et al., 2016; Curran et al., 2016), though
success has been reported in attenuating epileptogenesis
in adults (Jung et al., 2006; Maroso et al., 2010; Vezzani
et al., 2011a). Here, we administered the global anti-
inflammatory agent dexamethasone (DEX) shortly after
eFSE for a limited period, testing whether it suppressed
inflammatory cytokines and the formation of hyperexcit-
able networks (Dubé et al., 2000). DEX, a synthetic glu-
cocorticoid, inhibits expression of many cytokine genes,
including IL-1 (Jeon et al., 2000; Jang et al., 2007), via
the glucocorticoid receptor (GR; Reul et al., 1987). While
varied downstream effects of GR activation occur (Datson
et al., 2008; Groeneweg et al., 2012), the inhibition of
nuclear factor-B and a consequent transcription block of
key proinflammatory molecules likely mediate the anti-
inflammatory effects of DEX (Auphan et al., 1995; Gilmore,
2006). We found that transient DEX administration after
eFSE suppressed hippocampal hyperexcitability, likely by
preventing BBB leakage and elevation of hippocampal
cytokines.
Materials and Methods
Experimental overview
The goal of these experiments was to examine the role
of inflammatory processes, including BBB breaches, in
the proepileptogenic cascade that follows eFSE and cul-
minates in spontaneous seizures. Practical feasibility
issues governed the design of our experiments. Specifi-
cally, only 40% of eFSE-experiencing rats develop spon-
taneous seizures, and these are sparse, averaging less
than one seizure per week (Choy et al., 2014). Thus, it was
prohibitively costly in labor, time, and expense to perform
an adequately powered study that aimed to demonstrate
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significant reduction in seizure frequency from an already
low frequency, or reduction in the proportion of rats that
develop epilepsy when that proportion is only 33–40%.
Specifically, power analysis showed that to detect a 50%
reduction from a 40% seizure probability with an 0.8
power and   0.05 would require group sizes of 199 rats
(GPower, version 3.1.9.4).
Therefore, we used a surrogate marker approach that is
typical and acceptable in such scenarios: we identified a
marker of epileptogenesis, namely spike series, and ex-
amined the effects of DEX on this epilepsy-predicting
marker.
Four experiments were conducted. Experiment 1 deter-
mined the relation of spike series and spontaneous sei-
zures following eFSE. eFSE-experiencing rats and control
littermates were implanted with bilateral hippocampal
electrodes 2 months after the eFSE. Starting at approxi-
mately postnatal day 100 (P100), rats were chronically
recorded using video/EEG to detect spike series and
seizures. Rats were recorded in this manner until they
were 1 year of age.
Experiment 2 was performed after the first experiment
established that spike series always preceded spontane-
ous seizures provoked by eFSE. This experiment as-
sessed the effects of DEX on spike series, a measure of
hippocampal hyperexcitability after eFSE. The cohort was
implanted with EEG electrodes within 3 d after eFSE, and
video/EEGs were conducted for 4 weeks. Experimental
groups consisted of: control (non-eFSE) rats given vehicle
(CTL-VEH); DEX-treated control (non-eFSE) rats (CTL-
DEX); eFSE rats given vehicle (eFSE-VEH); and eFSE rats
provided with DEX (eFSE-DEX).
Experiment 3 examined the effects of post hoc DEX on
the acute proinflammatory cascades initiated by eFSE.
Controls and eFSE rats were included, and subgroups of
both received DEX immediately after the eFSE. Rats were
killed 3 h after the end of eFSE and hippocampi were
processed to measure mRNA levels of several proinflam-
matory mediators using RT-PCR.
Experiment 4 examined whether eFSE leads to the
breakdown of the BBB, and whether DEX administration
after the eFSE might attenuate BBB disruption. Rats (n 
25) were randomly assigned to undergo eFSE on P11 or
to serve as controls. Rats of both groups received either
vehicle or DEX following the eFSE. Twenty-four hours
later, rats underwent perfusion with fluorescein isothio-
cyanate (FITC)-conjugated albumin (FITC-albumin) and
then killed to examine for evidence of BBB leakage.
Procedure of experimental febrile status epilepticus
All animal procedures were approved by the University
of California-Irvine animal care committee and performed
according to NIH guidelines. The induction of eFSE has
been described in detail previously (Baram et al., 1997;
Dubé et al., 2010b; Patterson et al., 2015). Briefly,
Sprague Dawley rat pups were used for all studies on
postnatal day 10 or 11 based on their weight (Harlan;
RRID:RGD_5508397). Pups were placed, two at a time,
inside a 3 L glass container lined with absorbent paper.
Pups were subjected to a continuous stream of warm air
until behaviors indicating seizures began. These behav-
iors were a sudden arrest of hyperthermia-induced hyper-
kinesis (freezing) followed by chewing automatisms. Core
temperatures at the onset of the seizures (typically,
38.5°C) were rapidly measured and seizure-onset time
was noted. Once seizures commenced, elevated core
temperature and seizures were maintained via the warm
air stream for 40–60 min. Seizure behaviors typically
progressed over the hyperthermia period, including mild
chewing, clonic movements, and eventual tonic exten-
sion. Core temperature was measured every 2 min during
the eFSE. If the core temperature of the pups exceeded
41.5°C, they were removed from the chamber and placed
on a cool metal surface for the next 2 min. Cessation of
the hyperthermia promptly led to termination of the eFSE
and was facilitated by briefly immersing pups in cool
water (23.0°C). Pups were then dried and placed on a
euthermic pad maintained at 37°C for 20 min then re-
turned to their home cage and dam. In this study, all pups
subjected to hyperthermia experienced eFSE and there
was no eFSE-related mortality.
DEX administration
Following the eFSE and cooling, rats were administered
an intraperitoneal injection of DEX (3 mg/kg; Sigma-
Aldrich). The DEX dose was based on a large body of
literature using a wide range of doses of DEX for multiple
purposes (0.1–10 mg/kg). We chose 3 mg/kg because it
had been shown to fully suppress inflammation, and
used a short, tapered treatment course to avoid many of
the side effects (Quan et al., 2000; Duffy et al., 2014; Tsai
et al., 2016). Aldosterone was administered subcutane-
ously (0.2 g/100 mg; Acros Organics) to provide
mineralocorticoid functional support as DEX blocks en-
dogenous corticosterone production (Brunson et al.,
2001).
Rats undergoing video-EEGs (experiment 2) received
subsequent tapering doses of DEX (together with aldo-
sterone) over 48 h as follows: 1.5 mg/kg DEX 24 h after
eFSE; 0.75 mg/kg DEX 48 h after eFSE. Aldosterone was
continued for the next 4 d (seven treatments total) to
provide mineralocorticoid support during the potential
suppression of the adrenal glands of the rats. Rats used
for cytokine assessments (experiment 3) received a single
DEX dose and were killed 3 h after the end of eFSE.
Vehicle controls consisted of saline administered intra-
peritoneally.
EEG electrode implantation
For the first experiment, electrodes were implanted 2
months after eFSE. For the second experiment, elec-
trodes were implanted 3 d after eFSE. Rats were anes-
thetized under 1–3% isoflurane (Piramal Health Care) and
bipolar electrodes (Plastics One) were permanently in-
serted into both dorsal hippocampi [with reference to
bregma: P14: anteroposterior (AP), 2.7 mm; lateral (L), 1.8
mm; ventral (V), 2.2 mm; adult: AP, 3.6 mm; L, 2.6 mm;
V, 2.8 mm]. A cortical electrode was placed over the
parietal cortex (P14: AP, 2.0 mm; L, 1.5 mm; adult AP:
2.5 mm; L, 2.0 mm) and an additional ground electrode
was inserted over the cerebellar cortex. The whole cap
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was secured with OrthoJet Dental Cement (Lang Dental).
Following surgery, rats were kept on a warm pad for 1 h to
recover from anesthesia and then returned to their home
cages.
Video/EEG monitoring and analyses
All rats were recorded using video/EEG to examine for
eFSE-provoked alterations in hippocampal brain-wave
activity and the potential mitigating effects of DEX. Syn-
chronized videos served to categorize seizures using the
Racine scale, and, in some cases, to further exclude
potential movement artifact (e.g., from grooming).
Electrophysiological data were obtained at a frequency
band of 1–200 Hz and sampled at 400 Hz using Powerlab
8SP (AD Instruments; RRID:SCR_001620) equipped with
Chart 7 for Windows. The EEG tracings were synchro-
nized with video monitoring using a commercial video
camera (ZR40 Camcorder, Canon).
Rats from the first experiment were chronically re-
corded from 100 d after eFSE until the rats were 1 year
of age. The cohort has been described in the study by
Dubé et al. (2010b); however, the analyses reported have
not been published previously. For the second experi-
ment, video-EEG recordings commenced 2 d after elec-
trode implantation and continued for 4 weeks. Rats were
recorded for 2 h/d in amply bedded cages. These short
recording durations were necessary to ensure that the
pups received sufficient nutrition and maintained normal
growth curves. The order of recording of individual rats
and experimental groups was rotated daily to mitigate the
potential confounding effects of diurnal variation in hyper-
excitability. Four rats were monitored at a time, allowing
for concurrent recording of littermate controls and eFSE
animals. Hippocampal EEGs were acquired from freely
moving pups and were synchronized with video via both
the internal computer timer and a second, synchronized,
clock that was placed within the field of view of the video
camera.
EEG analyses
EEGs were acquired, registered, and analyzed using
LabChart 7 software (AD Instruments; RRID:
SCR_001620), and the records were re-evaluated using
an in-house algorithm (MATLAB, MathWorks; RRID:
nlx_153890; available on request). All video/EEGs were
analyzed without knowledge of treatment group by two
trained investigators. Spikes were defined as deflections
from a stable background with amplitudes more than
twice that of the background rhythms and durations of
20–70 ms. Spike series were defined as a minimum four
spikes occurring at a regular or semiregular interval from
a stable background within 5 s.
FITC-albumin administration and analyses of blood–
brain barrier integrity
FITC-albumin was used as a direct method to investi-
gate BBB permeability (Krueger et al., 2015; Breuer et al.,
2017). In preliminary experiments, we found that, on oc-
casion, the BBB was not fully mature in P10 rats. There-
fore, in this experiment, eFSE was always imposed on
P11 and BBB was examined at P12. Briefly, 24 h after
eFSE, rats (both male and female) underwent terminal
anesthesia induced with pentobarbital (Euthasol, Patter-
son Scientific). FITC-albumin was diluted to 10 mg/ml in
PBS, infused into the left ventricle at a rate of 1 ml/min (10
mL/kg), and allowed to circulate for 5 min. Rats were then
rapidly decapitated, and brains were removed and post-
fixed overnight in 4% paraformaldehyde. Brains were
cryoprotected in 30% sucrose, frozen, and sectioned
coronally at 30 m thickness.
Assessment of BBB breaches
A series of coronal sections from the septum through
the superior colliculus (with reference to bregma: anterior,
0.5 mm; posterior, 4.5 mm) was evaluated for evidence
of fluorescence extravasation by two observers who were
unaware of group assignment. Sections were viewed at
100 and suspicious areas were magnified. A BBB
breach was defined as FITC-albumin extravasation (i.e.,
fluorescence that was visible outside of clear vascular
boundaries) in areas free of tissue tears. The presence of
fluorescence inside glia was examined as well, and auto-
fluorescence was excluded using appropriate filters. The
numbers of extravasation areas per rat and their locations
were noted.
Quantitative real-time PCR
Whole hippocampi of both male and female rats, ob-
tained 3 h after the cessation of eFSE, were rapidly dis-
sected on ice using RNase-free instruments. Tissue was
immediately transferred to prechilled centrifuge tubes
kept on dry ice. Samples were stored at 80°C until use.
Total RNA was extracted from hippocampi using the mir-
Vana RNA Isolation Kit (Ambion) according to the manu-
facturer instructions. Double-stranded cDNA was
synthesized from total RNA using the Roche First Strand
cDNA Synthesis Kit (catalog #04379012001), with random
hexamer primers. Analysis of the PCR products used
cDNA samples in triplicate on a Roche Lightcycler 96
system. Samples were normalized to -actin and quanti-
fied using the cycle threshold method (2Ct; Schmittgen
and Livak, 2008). The primers used in this study are
shown in Table 1.
Immunohistochemistry
Rats were perfused under deep anesthesia as de-
scribed above for the BBB experiments. Alternate serial
sections from the same P12 rat brains used for FITC-
albumin analyses were used to visualize microglia and
astrocyte proliferation, which are cellular markers of neu-
roinflammation (Choy et al., 2014; Patterson et al., 2015).
Table 1: Primer designs
-Actin CAGCCTTCCTTCCTGGGTATGGAATC
CAGCACTGTGTTGGCATAGAGGTCTTTAC
COX2 TGGTGCCGGGTCTGATGATG
GCAATGCGGTTCTGATACTG
IL-1 GTGAAATAGCAGCTTTCGACAGTGAGGAG
GTGAGATTTGAAGCTGGATGCTCTCATCTG
IL-1R1 GCTTGTGACATCTTCGGCTA
AATGAACCCAAGTAGCACTTTCA
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First, sections were quenched with 0.9% hydrogen per-
oxide for 30 min in 0.01 M PBS with 0.3% Triton X-100
(PBS-T) and blocked in 5% normal goat serum (NGS;
catalog #R527-4001, Sigma-Aldrich) in 0.01 M PBS-T for 1
h. Then we incubated sections in primary antibody in 2%
NGS in PBS-T overnight at 4°C followed by incubation
with biotinylated mouse secondary antibody. Primary an-
tibodies included mouse anti-GFAP (1:1000; Millipore) for
delineating astrocytes and rabbit anti-P2Y12 (1:2000) for
selective labeling of microglia. Secondary antibodies were
goat anti-mouse (1:1000; catalog #BA-9200, Vector Lab-
oratories; RRID:AB_2336171) for 1 h and goat anti-rabbit
(1:400; catalog #BA-1000, Vector Laboratories; RRID:
AB_2313606) for 1.5 h, respectively. Subsequently, incu-
bation in Vectastain ABC-horseradish peroxidase kit
(catalog #PK-6100, Vector Laboratories; RRID:
AB_2336819) was performed for 2 h. We visualized the
immunoreactive signals using a DAB (diaminobenzidine)
Kit (catalog #SK-4100, Vector Laboratories; RRID:
AB_2336382) following the manufacturer recommenda-
tions. Sections were mounted on slides and coverslipped
using Permount Mounting Medium (catalog #SP15, Fisher
Chemicals).
Quantification of microglia and astrocytes
Quantification of microglia and astrocytes in hippocam-
pal CA1 and CA3 was achieved using a 1200  1200 m
grid for CA1 and a standardized 16,400 m2 trapezoid
grid for CA3. The tops of the grids were centered on the
“peak” of the CA1 pyramidal layer and on the most lateral
point of area CA3b in coronal sections of the dorsal
hippocampus. Counts and analyses of density were ac-
complished using the Fiji mode of ImageJ (NIH; RRID:
SCR_002285). For microglia, P2Y12 cells in the defined
region were counted and compared among groups, and
GFAP cells were quantified similarly for astrocytes. Anal-
yses considered the effects of eFSE and of DEX.
Statistical approaches and considerations
All analyses were performed without knowledge of
treatment group. Statistical analyses were performed us-
ing Prism 7 Software (GraphPad; RRID:SCR_002798),
and significance was set at 0.05. Datasets were initially
analyzed for outliers using Grubb’s Outlier Test ( 0.05),
and outliers, found exclusively in the quantitative real-time
PCR (qRT-PCR) data, were excluded. A two-way ANOVA
with Tukey’s multiple-comparisons post hoc test was
used to compare qRT-PCR results. Similarly, a two-way
ANOVA was used to examine BBB leakage across eFSE
and control rats with or without DEX treatment. To com-
pare BBB breaches and the number of rats with and
without spike series following eFSE, we used an on-line
calculator for Barnard’s unconditional exact test because
of its increased power for small sample sizes (Lydersen
et al., 2009; Ahmed, 2013). The D’Agostino-Pearson Nor-
mality Test was used before ANOVA to ensure normality.
The total number of spike series per animal and spike
series frequency (per recorded hour) were compared us-
ing Kruskal–Wallis ANOVA for datasets without normal
distribution. An observed versus expected goodness-of-
fit analysis was used to compare the percentage of rats
with spike series compared with previous short-term
measures of brain changes following eFSE.
Results
Spike series, denoting a hyperexcitable network,
precede spontaneous seizures after eFSE
The current experiments aimed to determine whether
the broad anti-inflammatory drug DEX prevented the ep-
ileptogenic process provoked by eFSE, which culminates
in spontaneous seizures (epilepsy). However, only 40% of
eFSE-experiencing rats develop spontaneous seizures.
The spontaneous seizures are sparse (less than one sei-
zure per week), and their onset is typically in young adult
or adult rats, with a latency of 	3 months (Dubé et al.,
2006, 2010b; Choy et al., 2014), though seizures are rarely
found earlier. Thus, the costs and duration of performing
an appropriately powered study, looking at the reduction
in seizure frequency from an already low level—or at a
reduction in the proportion of rats that develop epilepsy
when that proportion is only 33–40%—is prohibitive.
Therefore, the initial experiments aimed to identify an
earlier and more prevalent marker of the epileptogenic
process. Specifically, we investigated whether spike se-
ries were generated by eFSE and whether spike series
always preceded spontaneous seizures (Fig. 1A).
Spike series were never seen in our Sprague Dawley
controls, as was apparent from over 2400 h of recording
(Dubé et al., 2000, 2006, 2010b; Raol et al., 2003; Choy
et al., 2014). Therefore, spike series can be used as a
measure of abnormal hippocampal excitability in this con-
text (Staley and Dudek, 2006; Staley et al., 2011). In the
chronically video-EEG recorded eFSE-experiencing rats
(n  18), approximately a third had experienced neither
recorded spike series nor seizures (30.8%). A total of
64.3% of rats developed spike series, and the majority of
these (55.5%) progressed to spontaneous seizures
(35.7% of all rats that experienced eFSE). Notably, no rat
developed spontaneous seizures without prior spike se-
ries (Fig. 1B). Figure 1C–E provides representative EEGs
from dorsal hippocampus of these eFSE rats. Figure 1C
shows a typical multirhythm background. Figure 1D
shows spike series that can be unilateral or propagate to
both hippocampi. Figure 1E includes a typical hippocam-
pal seizure involving the left hippocampus with little prop-
agation, and we note that the rat was motionless during
this ictal event. Together, the data in Figure 1 indicate that
spike series precede spontaneous hippocampal seizures
after eFSE and define an abnormal, hyperexcitable hip-
pocampal network. Accordingly, spike series provide an
early and useful target for assessing the efficacy of anti-
epileptogenic interventions.
DEX attenuates the development and frequency of
spike series after eFSE
We assessed the presence, frequency, and duration of
spike series during the days and weeks following eFSE in
rats treated post hoc with DEX or vehicle (Fig. 2A). Neither
CTL-VEH nor CTL-DEX rats developed spike series
throughout the recording period, and the two groups were
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combined for further analysis. Representative bilateral
hippocampal EEG traces from a control rat are shown in
Figure 2B. Spike series were detected in EEGs from
eFSE-VEH rats and were mainly confined to a single
hippocampus (Fig. 2C, middle trace); a single eFSE-VEH
rat had a single electrographic seizure (Fig. 2C, bottom
trace). Notably, rats were immobile during recorded spike
series, as well as during the seizure. Quantitative analyses
revealed significant differences between the control and
eFSE-VEH groups in the proportion of rats that had spike
series (Barnard’s exact test, two-tailed, p  0.0062; Fig.
3A). Specifically, among eFSE-VEH rats, 41.6% (5 of 12)
had at least one spike series during the month following
eFSE. DEX significantly reduced this proportion: only 1 of
13 eFSE-DEX rats (7.6%) had at least one spike series
during the same recording time, a significantly lower risk
than the eFSE-VEH group (Barnard’s exact test, two-
tailed, p  0.031). Indeed, the probability of having spike
series was not significantly different in the control and
eFSE-DEX groups (Barnard’s exact test, two-tailed, p 
0.37).
The number of spike series per animal was higher in the
eFSE-VEH group (4.33 
 9.96) than in controls (0 
 0.0;
Kruskall-Wallis [K-W] ANOVA for nonparametrically dis-
tributed data). ANOVA demonstrated a mean rank differ-
ence of 8.083 (p  0.01, Dunn’s multiple-comparisons
Figure 1. Spike series precede seizures in rats rendered epileptic by eFSE. A, Experimental design. P10–P11 male rats underwent
eFSE (n  18) and electrode implantation at P60. Rats were then recorded until 1 year of age. B, eFSE-induced hyperexcitability
in a proportion of rats, apparent as spike series alone (28.6% of rats that underwent eFSE; yellow bar) or spike series followed by
seizures (35.7% of eFSE rats; red bar). No rat developed seizures before the onset of spike series. C–E, Representative examples of
baseline EEG of an adult rat that underwent eFSE, an example of a spike series, and an example of a seizure. Whereas the spike series
and seizure emanate from the left hippocampus here and in Figure 2, there was no overall propensity to either side in the overall study
and none in prior ones (Dubé et al., 2006, 2010b).
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test; Fig. 3B). Importantly, the mean number of spike
series per animal in the eFSE-DEX group did not differ
significantly from the value in controls (K-W ANOVA:
eFSE-DEX mean, 0.23 
 0.83; mean rank difference,
1.53; p  0.999). In addition, there was a 	90% reduc-
tion in the mean number of spike series when the eFSE-
VEH and eFSE-DEX groups were compared (eFSE-VEH,
4.33; eFSE-DEX, 0.23; mean rank difference, 6.55; p 
0.067).
To account for variances in recording times, we com-
pared across groups the frequency of spike series per
hour recorded and identified significant group differences
(Fig. 3C). Spike-series frequency was higher in the eFSE-
VEH group compared with controls (CTL mean, 0 
 0,
Figure 2. The effects of DEX on immature rat EEG following eFSE. A, Experimental design: rats underwent eFSE at P10 or P11 and
were then given tapering doses of DEX (1 h, 3 mg/kg; 24 h, 1.5 mg/kg; 48 h, 0.75 mg/kg). Mineralocorticoid support was provided
by concurrent doses of aldosterone. Electrodes were implanted at P13, and rats were then video recorded with concurrent EEGs for
1 month. B, Representative EEG from a control rat. C, Representative traces of baseline EEG (top), a spike series (middle), and a single
example of a seizure from a rat that had undergone eFSE and received vehicle treatment. For all EEG traces, the scale on left is in
millivolts. Thin vertical bars delineate 0.25 s, and the bold vertical bars are at 1 s intervals.
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eFSE-VEH mean, 0.029 
 0.06; K-W ANOVA: K-W sta-
tistic, 9.71; mean rank difference, 8.29; p  0.01;
Dunn’s multiple-comparisons test). DEX significantly re-
duced the frequency of spikes (eFSE-DEX vs eFSE-VEH
groups, p  0.046; K-W ANOVA, mean rank difference,
6.95). Indeed, spike series frequency in the eFSE-DEX
group did not differ significantly from that in controls
(eFSE-DEX mean, 0.0007 
 0.002; K-W ANOVA: mean
rank difference, 1.35; p  0.99). The duration of each
spike series was variable both within individual rats and
across rats, ranging from 3 to 258 s. Because only one rat
in the eFSE-DEX group had spike series, differences in the
mean duration of spike series among groups could not be
statistically compared. As is apparent from Figure 3D, the
average duration of spike series in the single eFSE-DEX
rat that had them was not notably different from the
duration of spike series in the eFSE-VEH group.
In both humans and rodents, epilepsy develops in only
a subgroup of individuals after FSE (or eFSE; Annegers
et al., 1987; Dubé et al., 2006, 2010b; Choy et al., 2014).
Seeking to identify predictors of epilepsy development in
individual rats, we have previously identified epilepsy-
predictive MRI T2 signal changes in limbic structures in
42% (8 of 19) of all eFSE rats at 2 h following eFSE
(Choy et al., 2014). Considering this prior knowledge, we
examined whether the prevalence of hyperexcitability
(spike series) in the eFSE-VEH group was similar to the
prior findings, and whether it was influenced by DEX
administration. We used observed versus expected
goodness-of-fit analysis and set the predicted/expected
hyperexcitability prevalence as 45%. In the eFSE-VEH
group, the observed prevalence of hyperexcitability, de-
fined as the presence of spike series, was not significantly
different from the expected 45% (p 	 0.99). In contrast,
observed prevalence in the eFSE-DEX group was signifi-
cantly lower from expected prevalence (p  0.009). To-
gether, the data and analyses above demonstrated that
transient administration of DEX following eFSE reduced
the probability of developing a hyperexcitable hippocam-
pal network.
Figure 3. DEX administration following eFSE decreases hippocampal hyperexcitability. A, DEX attenuated the proportion of rats with
recorded spike series (unconditional Barnard’s exact test, control vs eFSE-VEH, p  0.0062; eFSE-VEH vs eFSE-DEX, p  0.031;
control vs eFSE-DEX, p  0.37). B, DEX reduced the mean number of spike series per rat (Kruskal–Wallis ANOVA: mean rank
difference, 8.083; p  0.01; Dunn’s multiple-comparisons test, eFSE-DEX vs controls: mean rank difference, 1.53; p  0.999;
eFSE-VEH vs eFSE-DEX: mean rank difference, 6.55; p  0.067). C, DEX attenuated the mean spike series frequency (spike
series/hour recorded) to control levels (CTL mean, 0
 0; eFSE-VEH mean, 0.029
 0.06; K-W ANOVA: K-W statistic, 9.71; mean rank
difference, 8.29; p  0.01; Dunn’s multiple-comparison test, eFSE-DEX vs eFSE-VEH: mean rank difference, 6.95; p  0.046;
eFSE-DEX vs controls: mean rank difference, 1.35; p  0.99). D, There was no notable difference between the mean durations of
the spike series among groups. p  0.05.
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Neuroinflammatory cytokine production following
eFSE is attenuated by DEX
Having identified that DEX suppressed the develop-
ment of spike series after eFSE, we next addressed the
potential mechanisms. Specifically, we examined whether
eFSE generated an inflammatory response in the hip-
pocampus in a subset of eFSE rats, and whether DEX
attenuated this inflammation. We assessed neuroinflam-
mation using two independent quantitative approaches:
we measured the rapid upregulation of proinflammatory
mRNA transcripts as well as the proliferation of astrocytes
and microglia.
We used qRT-PCR to analyze mRNA levels of several
inflammatory mediators that are rapidly augmented by
eFSE (Dubé et al., 2005; Patterson et al., 2015), as well as
other models of status epilepticus (Jiang et al., 2010;
Vezzani et al., 2011b; Fig. 4A), and that have been impli-
cated in the epileptogenesis that follows eFSE (Dubé
et al., 2010a; Choy et al., 2014; Patterson et al., 2015).
Levels of IL-1 mRNA in hippocampi of experimental rats
3 h after the end of eFSE were compared with those of
controls. eFSE and DEX treatment both had a significant
effect on IL-1 mRNA levels (two-way ANOVA: eFSE:
F(1,22)  9.61; p  0.005; DEX treatment: F  6.92, p 
0.02) and the effects of eFSE and DEX treatment inter-
acted (F  14.36; p  0.001). Thus, eFSE significantly
increased the production of IL-1 in eFSE-VEH rats com-
pared with the CTL-VEH group (p  0.0018, Tukey’s
multiple comparisons). There was a significant reduction
in IL-1 levels in eFSE-DEX-treated rats versus eFSE-VEH
treated rats (p  0.0003). In fact, DEX administration after
eFSE rendered the levels of hippocampal IL-1 mRNA
statistically similar to those of CTL-VEH rats (p  0.98;
Fig. 4B).
Levels of IL-1R1 mRNA were also influenced by group.
eFSE affected mRNA production of IL-1R1 (two-way
ANOVA Tukey’s multiple-comparisons test:, eFSE: 44%
of total variance; F(1,21)  18.81; p  0.0003). DEX re-
Figure 4. DEX administration reduces the expression of inflammatory molecules provoked by eFSE. A, Experimental design: rats of
both sexes underwent eFSE at P10–P11. The rats were killed and hippocampi were rapidly dissected 4 h from eFSE onset. B–D, At
the group level, post hoc eFSE increased expression of IL-1 (B), and IL-1R1 (C), DEX administration significantly decreased the mRNA
expression of IL-1 and tended to reduce COX2 expression (D), all analyzed using two-way ANOVA followed by Tukey’s multiple
comparisons. IL-1: eFSE: 18.5% variance; F(1,22) 9.61; p 0.005; DEX treatment: 13.3% total variance; F(1,22) 6.92; p 0.02; IL-1R1:
eFSE: 44% total variance; F(1,21)  18.81; p  0.0003; DEX treatment: 1.6% total variance; F(1,21)  0.70; p  0.41. eFSE-VEH versus
eFSE-DEX, p 0.012. COX2: effect of eFSE: 7.74% total variance; F(1,19) 2.09; p 0.17; effect of DEX treatment: 14.39% variance; F(1,19)
 3.88; p  0.06. CTL-VEH versus eFSE-DEX, p  0.98; eFSE-VEH versus eFSE-DEX, p  0.20. p  0.05, p  0.01, p  0.0005.
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duced IL-1R1 mRNA levels in eFSE-DEX rats compared
with the eFSE-VEH rats (p  0.012) and rendered the
levels of hippocampal IL-1R1 mRNA in eFSE-DEX rats
statistically indistinguishable from those of CTL-VEH rats
(p  0.12; Fig. 4C). The anti-inflammatory effect of DEX
was also apparent in controls as a significant reduction in
IL-1R1 levels in the CTL-DEX rats compared with the
CTL-VEH rats (p  0.046). mRNA levels of COX2 did not
reveal statistically significant group differences (two-way
ANOVA; effect of eFSE: F  2.09; p  0.17; effect of DEX:
F  3.88; p  0.06). However, there was much heteroge-
neity in the eFSE-VEH group with regard to the expression
of this proinflammatory enzyme, likely reflecting the fact
that COX2 levels peak later, at 24 h after eFSE (Patterson
et al., 2015). DEX administration decreased COX2 levels
following eFSE so that the eFSE-DEX group was indistin-
guishable from the CTL-VEH group (p  0.98; Fig. 4D).
Together, these findings suggest a rapid upregulation
of proinflammatory cytokines and receptors within 3 h
after eFSE. Whereas at this the early time point we did not
examine protein expression, our previous studies have
shown excellent congruence between inflammatory
mRNA changes and corresponding variations in protein
expression as measured by Western blot (Patterson et al.,
2015).
Hippocampal microglia and astrocytes: effects of
eFSE and of DEX
Proliferation and morphologic changes in the shape of
microglia and astrocytes is a common inflammatory re-
sponse to insults that provoke epilepsy (Aronica and
Crino, 2011; Vezzani et al., 2011b). eFSE, which does not
provoke cell death (Dubé et al., 2007, 2010b), results in a
modest glial response. As found previously (Patterson
et al., 2015), microglial density in hippocampal subfields
CA1 and CA3 was not influenced significantly by eFSE
(Fig. 5). Notably, in area CA1, DEX reduced microglial
density in both eFSE and control hippocampi consistent
with its established anti-inflammatory actions (two-way
ANOVA; main effect of DEX, p  0.0165). For astrocytes,
our analyses at 24 h after the end of the eFSE did not
reveal the effects of either eFSE or DEX (Fig. 6). Together,
these findings suggest that eFSE provokes the extremely
rapid mRNA expression of proinflammatory cytokines
such as IL-1, and these precede and perhaps contribute
to glial proliferative reactions.
BBB is disrupted by eFSE, an effect attenuated by
DEX administration
We examined whether augmented permeability of the
BBB takes place after eFSE and may contribute to the
observed hippocampal neuroinflammatory cascades that
promote epileptogenesis (Bar-Klein et al., 2017; Kim et al.,
2017; Koepp et al., 2017; Rüber et al., 2018). To visualize
BBB permeability, we used an infusion of FITC-albumin,
which is typically excluded from the brain by the BBB tight
junctions (Fig. 7J; Wolburg and Lippoldt, 2002). Sections
from brains of control rats, regardless of DEX administra-
tion (n  12), did not reveal any extravasation of the
FITC-albumin (Fig. 7A,A=,D,D=,G,G=). Therefore, the DEX-
and vehicle-receiving control groups were combined for
further analyses. In contrast, abnormal extravasation of
FITC-albumin was apparent in sections from five of eight
eFSE-VEH rats (62.5%), measured as increased fluores-
cence within the parenchyma and occasionally within
somata (Fig. 7B,B=,E,E=,H,H=). Common areas of BBB
breach included cortex, both somatosensory and entorhi-
nal (Fig. 7), and the mediodorsal nucleus of the thalamus.
Notably, extravasation was not observed in hippocam-
pus. Statistical analysis identified a significant difference
between controls versus eFSE-VEH (Fig. 7K; Barnard’s
exact test, two-sided, p  0.001; score, 3.162), but no
difference between controls and eFSE-DEX, revealing
that DEX treatment following eFSE reduces the risk of
BBB extravasation to that of control rats (Barnard’s exact
test, two-sided, p  0.12; score, 1.60).
Discussion
Here we find that (1) eFSE generates a proepileptogenic
hyperexcitable hippocampal network; (2) this hyperexcit-
ability, apparent as the presence of spike series, is ac-
companied by an acute molecular and cellular
neuroinflammatory reaction and a breach of the BBB; (3)
these disturbances occur in a subset of rats, in accord
with FSE-provoked epileptogenesis in rodents and hu-
mans; and (4) the proepileptogenic consequences of
eFSE are attenuated by a post hoc short course of the
clinically available drug dexamethasone.
Spike series are a surrogate marker of eFSE-
induced epileptogenesis and enable designing
mechanistic interventional studies
In children, TLE develops in a subgroup of those expe-
riencing FSE with 10–12 year latency (Seinfeld et al.,
2016), which prohibits the design of adequately powered
intervention strategies. (Hesdorffer et al., 2012). There-
fore, as is common throughout clinical intervention trials,
markers are sought that can be detected early and indi-
cate a high risk for eventual disease (Barker-Haliski et al.,
2014). For FSE, the FEBSTAT study obtained early EEGs,
cytokines, and MRIs as potential surrogate markers of
epileptogenesis (Nordli et al., 2012; Lewis et al., 2014;
Gallentine et al., 2017). In the current animal model, only
40% of eFSE rats develop spontaneous seizures, and
these are sparse (Choy et al., 2014). To avoid the prohib-
itive cost of adequately powered studies (required, n 
199/group; see Materials and Methods) required to dem-
onstrate a significant reduction in seizure prevalence or
frequency from already low levels, we used a surrogate
marker. We established that spontaneous seizures never
occurred without prior spike series, and, whereas not all
animals with spike series developed epilepsy, spike series
were a sensitive surrogate marker for epileptogenesis.
Compared with the predictive MRI signal identified previ-
ously (Choy et al., 2014), spike series are a more direct
indicator of aberrant neuronal firing, useful for efficient
preventative trials. Here we examined the effects of DEX
on this surrogate marker (Barker-Haliski et al., 2014).
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Figure 5. DEX reduces microglial density in both eFSE and control hippocampi. A–D=, Representative samples of P2Y12 cells in the
CA1 and CA3 regions of the hippocampi of CTL-VEH (A, A=), CTL-DEX (B, B=), eFSE-VEH (C, C=), and eFSE-DEX rats (D, D=). E, F,
We did not find an increase in the number of microglia in the CA1 (E) or CA3 (F) of rats 24 h after undergoing eFSE, but DEX
administration did reduce the number of microglia in eFSE and control rats (two-way ANOVA; main effect of DEX, p  0.0165). Scale
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Acute rapid inflammatory processes initiated by
eFSE in a subset of individuals require early
intervention
Neuroinflammation has been demonstrated after hu-
man FSE and in rodent FSE models (Heida and Pittman,
2005; Reid et al., 2013; Gallentine et al., 2017). We have
previously found that inflammatory cytokines are both
required for eFSE generation and are upregulated by the
seizures (Dubé et al., 2005, 2010b; Patterson et al., 2015).
Furthermore, whereas only a subset of rats sustained
inflammation, these same rats had MRI changes that
predicted epileptogenesis (Patterson et al., 2015). Here
we demonstrate rapid elevations of IL-1, IL-1R1, and
COX2 already at 3 h from the eFSE. While this elevation
was not significant on group levels for IL1-R1 and COX2,
it occurred in 40% of rats, which is consistent with
previous work and the proportion of rats developing epi-
lepsy (Patterson et al., 2015). The remarkable rapidity of
the inflammatory response that follows eFSE provides the
rationale for initiating anti-inflammatory intervention within
hours of the eFSE, as done here.
eFSE-induced neuroinflammation: a function of age
and seizure type?
We further delineated the sequence of neuroinflamma-
tory events initiated by eFSE and lasting for a minimum
72 h (Dubé et al., 2010b; Patterson et al., 2015). Prior
work identified translocation of high-mobility group box1
(HMGB1) from neuronal nuclei to cytoplasm for export,
within an hour from eFSE (Choy et al., 2014). HMGB1
interacts with glial inflammatory receptors (e.g., toll-like
receptor 4), activating astrocytes and microglia. Here,
cytokine mRNA production was found already within 3 h
from the end of the eFSE, and protein expression was
confirmed previously using Western blots. At single-cell
resolution, immunohistochemistry showed IL1 produc-
tion in astrocytes but not in microglia (Dubé et al., 2010b).
IL-1 production does not derive from the proliferation or
migration of astrocytes and microglia: even by 24 h after
eFSE, there was no hippocampal astrocytosis or micro-
gliosis. The increased levels of IL-1 production, ob-
served already at 3 h, may contribute to BBB disruption,
which was apparent by 24 h after eFSE (Vezzani and
Baram, 2007).
The neuronal to glial progression of neuroinflammation
and its distinct molecular patterns may stem from the fact
that eFSE takes place in an immature brain and does not
provoke cell death, likely because of the resilience of
immature neurons to excitotoxicity (Dubé et al., 2000;
Sullivan et al., 2003). Hence, the inflammation is not a
response to neurodegeneration and may contribute di-
rectly to the formation of an epileptic network (Vezzani
and Baram, 2007).
Disruption of the BBB 24 h after eFSE
The current work uncovered BBB disruption by eFSE.
Whereas the BBB is not fully mature in neonatal rats, it
appears to be functional in P12 Sprague Dawley rats
reared in defined conditions that standardize body weight
and brain development. Thus, in control pups, the BBB
excluded FITC-albumin from brain parenchyma in 12 of
12 pups. In contrast, BBB permeability was increased in a
subset of eFSE rats 24 h later, with FITC-albumin extrav-
asation in the entorhinal, frontoparietal, and piriform cor-
tices, and the mediodorsal nucleus of the thalamus. These
areas of disruption are intriguing for two reasons. First,
they are a component of the limbic circuitry involved in
TLE-like limbic epilepsy. In addition, prior literature on
SE-induced injury in the developing brain has identified
the medial thalamus as sensitive to injury after SE in
immature rats (Kubová et al., 2002), and MRI changes in
medial thalamus were predictive of epileptogenesis after
eFSE (Choy et al., 2014). Additionally, the piriform cortex
has been shown to be particularly sensitive to SE-
provoked BBB breakdown, and this permeability was
predicative of epileptogenesis (van Vliet et al., 2014; Bar-
Klein et al., 2017). Interestingly, BBB disruption was not
observed in the hippocampus per se, but rather in the
interconnected cortical and thalamic regions noted
above.
The role of BBB in epileptogenesis has been a topic of
intense study. Support for the mechanistic role of BBB
disruption in epileptogenesis was provided by Bar-Klein
et al., 2014, who demonstrated antiepileptogenic effects
of targeting the processes underlying BBB disruption. We
can only speculate if BBB disruption after eFSE is causally
involved in epileptogenesis. At a minimum, the BBB leak-
age represents a component of an inflammatory cascade
that was attenuated by early administration of DEX.
The rationale for DEX, and its promise
The combined findings of this and prior studies high-
light the fact that multiple inflammatory cascades in sev-
eral types of cell pathways are initiated by eFSE. These
pathways are intercalated via numerous feedback loops
and compensatory processes. This suggested that inter-
fering specifically with only one of these processes might
not suffice to prevent epileptogenesis, prompting the use
of the broad anti-inflammatory agent DEX.
Indeed, a number of more specific other anti-
inflammatory approaches have not been successful in
preventing epileptogenesis. Holtman et al. (2009, 2010)
used several agents including COX2 inhibitors with little
success in adult SE. Jiang et al. (2010, 2013) found neu-
roprotective, but not antiepileptogenic, effects of blocking
the EP2 pathway. These studies and others have sug-
gested that selective approaches to specific inflammatory
cascades might have limited potential, at least in part
because of the complex interplay and balance among the
numerous inflammatory processes triggered by insults, a
view supported by Brennan et al. (2016), who targeted
miR124. Whereas, more recently, Terrone et al. (2018)
reported on success in attenuating epileptogenesis by
targeting the IL-1 pathway and Henshall (2017) capital-
continued
bars: 200 m; inset, 50 m. p  0.05.
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Figure 6. eFSE and DEX do not change the density of astrocytes following eFSE. A–D=, Representative samples of GFAP cells in
the CA1 and CA3 regions of the hippocampi of CTL-VEH (A, A=), CTL-DEX (B, B=), eFSE-VEH (C, C=), and eFSE-DEX rats (D, D=). We
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ized on the ability to manipulate microRNAs in adults, we
chose here to use a broad anti-inflammatory approach,
hoping to obviate feedback or compensatory changes
within the complex inflammatory network (Vezzani et al.,
2011a; Brennan et al., 2016).
DEX is a broad and powerful anti-inflammatory agent,
approximately five times more potent than prednisone,
and, at the doses used here, it rapidly crosses the blood–
brain barrier, a concern whenever dealing with therapeu-
tics in the brain (van de Waterbeemd et al., 1998).
Additionally, DEX is clinically available and widely used in
children; its costs and mode of administration are man-
ageable, enabling potential clinical application. Therefore,
the finding that DEX significantly attenuated both proin-
flammatory mediators and spike series, a measure of
network hyperexcitability, is encouraging.
continued
did not find an increase in the number of astrocytes in the CA1 (E) or CA3 (F) of rats 24 h after undergoing eFSE or with DEX
administration (two-way ANOVA; main effect of eFSE, p  0.30; DEX p  0.43). Scale bars: 200 m; inset, 50 m.
Figure 7. eFSE induces increased permeability of the BBB to albumin, which is attenuated by post-eFSE DEX administration. A–I,
Representative examples of FITC-albumin in control rats, eFSE-VEH rats, and eFSE-DEX rats in the somatosensory cortex, thalamus,
and entorhinal cortex. Extravasation can be seen in B, E, and H as the FITC-albumin spreading outside of the vasculature. J,
Experimental design: rats underwent eFSE at P11 and received two tapering doses of DEX. Rats were infused with FITC-albumin and
killed 5 min later. K, There was a significant increase in prevalence of rats that had extravasation between controls versus eFSE-VEH
(Fig. 6K; Barnard’s exact test, two-sided, p 0.001; score,3.162), but no difference between controls and eFSE-DEX, revealing that
DEX treatment following eFSE reduces the risk of BBB extravasation to that of control rats (Barnard’s exact test, two-sided, p 0.12;
score, 1.60. p  0.05. n.s., Not significant. Scale bar, 100 m.
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Potential limitations and future studies
The aberrant hyperexcitability addressed in the current
studies was elicited by eFSE in immature rats. TLE asso-
ciated with eFSE involves minimal cell death and might
thus be easier to prevent than chemoconvulsant-induced
epileptogenesis in adults. In contrast, the nature and du-
ration of the insult, the age of affected individuals, MRI
changes, and the proportion of individuals who develop
spontaneous seizures approximate those in humans ex-
periencing FSE. Therefore, our results, while not general-
izable to adults, should carry major significance for FSE-
related TLE.
Several questions remain. Memory and related cogni-
tive problems develop in children experiencing FSE
(Weiss et al., 2017); we have recently identified these
problems in eFSE rats (Dubé et al., 2009; Patterson et al.,
2017). Future work will test whether DEX has protective
effects on cognition. Notably, we used a high DEX dose.
While no obvious deleterious effect was noted in acutely
DEX-treated rats, dosing and potential adverse effects
should be addressed.
In summary, the contribution of FSE to common and
often serious epilepsy has been established. Here we
provide novel evidence for the role of brain inflammation
in the epileptogenesis that follows eFSE. Importantly, we
attenuated eFSE-induced hippocampal hyperexcitability
by dampening inflammatory mediators using a clinically
available anti-inflammatory agent.
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